Geode Capital Management
WHWK

Geode Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Geode Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.12M Buy
899,780
+442,240
+97% +$1.84M ﹤0.01% 2996
2026
Q1 		$1.58M Buy
457,540
+32,100
+8% +$100K ﹤0.01% 3214
2025
Q4 		$1.03M Buy
425,440
+43,686
+11% +$100K ﹤0.01% 3368
2025
Q3 		$726K Buy
381,754
+9,420
+3% +$17.3K ﹤0.01% 3490
2025
Q2 		$696K Buy
372,334
+136,494
+58% +$238K ﹤0.01% 3449
2025
Q1 		$420K Buy
235,840
+18,546
+9% +$48.4K ﹤0.01% 3610
2024
Q4 		$686K Buy
217,294
+8,546
+4% +$19.4K ﹤0.01% 3499
2024
Q3 		$430K Buy
208,748
+2,305
+1% +$3.73K ﹤0.01% 3648
2024
Q2 		$301K Sell
206,443
-192,788
-48% -$357K ﹤0.01% 3764
2024
Q1 		$934K Buy
399,231
+3,374
+0.9% +$6.5K ﹤0.01% 3388
2023
Q4 		$800K Buy
395,857
+29,079
+8% +$122K ﹤0.01% 3435
2023
Q3 		$1.78M Buy
366,778
+34,265
+10% +$199K ﹤0.01% 3110
2023
Q2 		$2.27M Buy
332,513
+60,814
+22% +$473K ﹤0.01% 3070
2023
Q1 		$1.97M Buy
271,699
+10,613
+4% +$113K ﹤0.01% 3039
2022
Q4 		$3.35M Buy
261,086
+4,681
+2% +$61.1K ﹤0.01% 2860
2022
Q3 		$3.62M Sell
256,405
-55,312
-18% -$727K ﹤0.01% 2846
2022
Q2 		$3.84M Buy
311,717
+114,533
+58% +$1.7M ﹤0.01% 2837
2022
Q1 		$3.35M Buy
197,184
+111
+0.1% +$2.13K ﹤0.01% 3002
2021
Q4 		$4.76M Buy
197,073
+168,970
+601% +$4.24M ﹤0.01% 2925
2021
Q3 		$825K Buy
28,103
+6,343
+29% +$193K ﹤0.01% 3789
2021
Q2 		$551K Buy
21,760
+4,495
+26% +$103K ﹤0.01% 3897
2021
Q1 		$334K Buy
17,265
+7,142
+71% +$164K ﹤0.01% 3952
2020
Q4 		$148K Buy
10,123
+1,973
+24% +$42.2K ﹤0.01% 3973
2020
Q3 		$183K Buy
8,150
+490
+6% +$10.3K ﹤0.01% 3745
2020
Q2 		$143K Hold
7,660
– – ﹤0.01% 3762
2020
Q1 		$63K Hold
7,660
– – ﹤0.01% 3882
2019
Q4 		$71K Hold
7,660
– – ﹤0.01% 4032
2019
Q3 		$77K Hold
7,660
– – ﹤0.01% 4005
2019
Q2 		$104K Hold
7,660
– – ﹤0.01% 3952
2019
Q1 		$103K Buy
+7,660
New +$330K ﹤0.01% 3890

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's WHWK Position: Q2 2026 in Review

Geode Capital Management increased its Whitehawk Therapeutics (WHWK) stake by 97% in Q2 2026, buying an estimated $1.84M and bringing the position to 899,780 shares worth $4.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Geode Capital Management first reported a position in WHWK in Q1 2019 and has held it in 30 quarters since. The position peaked at $4.76M in Q4 2021. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Geode Capital Management held 899,780 shares of Whitehawk Therapeutics worth $4.12M as of Q2 2026.
  • Geode Capital Management bought 442,240 Whitehawk Therapeutics shares in Q2 2026, an estimated $1.84M.
  • Whitehawk Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2996 holding.
  • Geode Capital Management first reported a position in Whitehawk Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Geode Capital Management's Whitehawk Therapeutics position peaked at $4.76M in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.